Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-04-14
2010-02-23
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S388100, C530S388200, C530S388700
Reexamination Certificate
active
07667007
ABSTRACT:
The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to αvβ3, or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Additionally provided are methods of inhibiting a function of αvβ3by contacting αvβ3with an enhanced LM609 grafted antibody.
REFERENCES:
patent: 5225539 (1993-07-01), Winter
patent: 5264563 (1993-11-01), Huse
patent: 5523388 (1996-06-01), Huse
patent: 5578704 (1996-11-01), Kim et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5766591 (1998-06-01), Brooks et al.
patent: 6096551 (2000-08-01), Barbas et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6531580 (2003-03-01), Huse et al.
patent: 6590079 (2003-07-01), Huse et al.
patent: 6596850 (2003-07-01), Huse
patent: 6887473 (2005-05-01), Brooks et al.
patent: 7371382 (2008-05-01), Huse et al.
patent: 7422744 (2008-09-01), Huse et al.
patent: 0 451 216 (1991-10-01), None
patent: 0 682 040 (1993-11-01), None
patent: WO 95/25543 (1995-09-01), None
patent: WO 96/40250 (1996-12-01), None
patent: WO 98/33919 (1998-08-01), None
MacCallum et al., J. Mol. Biol. 262: 732-745, 1996.
Padlan et al., PNAS 86: 5938-5942, 1989.
Lamminmaki et al., J. Biol. Chem. 276: 36687-36694, 2001.
Adams et al., “Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies,”Cancer Res.58:485-490 (1998).
Alfthan, “Surface Plasmon resonance biosensors as a tool in antibody engineering,”Biosensors and Bioelectronics, 13:653-663 (1998).
Biedler, “Mammalian expression and characterization of a dimeric single chain antibody specific for integrin alpha-v-beta-3,”Immunotech., 2:297 (1996).
Biotechnology Newswatch, pp. 11 (Feb. 6, 1995).
Biotechnology Newswatch, pp. 11-12 (Jan. 16, 1995).
Brooks et al., “Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.,”Cell79:1157-1164 (1994).
Carmeliet, “Integrin indecision,”Nature Medicine8:14-16 (2002).
Chen et al., “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations,”EMBO J., 14:2784-2794 (1995).
Cheresh et al., “Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor,”J. Biol. Chem.262(36):17703-17711 (1987).
Cheresh et al., “Integrin-mediated death: An explanation of the integrin-knockout phenotype?”Nature Medicine8:193-194 (2002).
Cheresh, “Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion redeptor involved in attachment to fibrinogen and von Willebrand factor,”Proc. Natl. Acad. Sci. USA84:6471-6475 (1987).
Choi et al., “Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA,”J. Vascular Surg., 19:125-134 (1994).
Chothia et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,”J. Mol. Biol.196:901-917 (1987).
Chowdhury et al., “Improving antibody affinity by mimicking somatic hypermutation in vitro,”Nature Biotech.17:568-572 (1999).
Clark, “Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man,” Nottingham, England: Academic Titles (1993).
Colman, Effects of amino acid sequence changes on antibody-antigen interactions,Res Immunol., 145:33-36 (1994).
Davies et al., “Affinity improvement of single antibody VH domains: Residues in all three hypervariable regions affect antigen binding,”Immunotech., 2:169-179 (1996).
Day,Advanced Immunochemistry, Second Ed., Wiley-Liss, Inc., New York, NY (1990).
Devlin et al., “Random peptide libraries: a source of specific protein binding molecules,”Science249:404-406 (1990).
Dorland'S Illustrated Medical Dictionary, Twenty-sixth Ed. W.B. Saunders Company, Philadelphia, 1981, p. 385.
Dueñas et al., “Selection of Phage Displayed Antibodies Based on Kinetic Constants,”Molec. Immunol., 33(3):279-285 (1996).
Foote et al., “Kinetic maturation of an immune response,”Nature352:530-532 (1991).
Glaser et al., “Antibody engineering by codon-based mutagenesis in a filamentous phage vector system,”J. Immunol.149:3903-3913 (1992).
Hawkins et al., “Selection of phage antibodies by binding affinity. Mimicking affinity maturation,”J. Mol. Biol., 226:889-896 (1992).
Huse et al., “Application of a Filamentous Phage pVIII Fusion Protein System Suitable for Efficient Production, Screening, and Mutagenisis of F(ab) Antibody Fragments,”J. Immunol.149:3914-3920 (1992).
Huse, “Combinatorial Antibody Expression Libraries in Filamentous Phage,” In: Antibody Engineering: A Practical Guide, C.A.K. Borrebaeck, ed. W.H. Freeman and Co., Publishers, New York, pp. 103-120 (1991).
Huston et al., “Antigen Recognition and Targeted Delivery by the Single-Chain Fv,”Cell Biophysics, 22:189-224 (1993).
Kabat et al., U.S. Dept. of Health and Human Services, “Sequences of Proteins of Immunological Interest,” vol. 1 pp. i-xcvi (1991).
Kussie et al., “A single Engineered Amino Acid Substitution Changes antibody Fine Specificity,”J. Immunol.152:146-152 (1994).
Moore et al., “Directed evolution of a para-nitrobenzyl esterase for aqueous-organic solvents,”Nat Biotechnol.14:458-467 (1996).
Morrison et al., “Genetically Engineered Antibody Molecules,”Adv. Immunol., 44:65-92 (1989).
Myszka et al., “Kinetic analysis of a protein antigen-antibody interaction limited by mass transport on an optical biosensor,”Biophys. Chem., 64:127-137 (1997).
Newman et al., ““Primatization” of Recombinant Antibodies for Immunotherapy of Human Diseases: A Macaque/Human Chimeric Antibody Against Human CD4,”Biotechnol., 10:1455-1460 (1992).
Padlan, “A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties,”Molecular Immunol., 28(4/5):489-498 (1991).
Plũckthun et al., “Expression of functional antibody Fv and Fab fragments inEscherichia coli,” Meth. Enzymol.178-497-515 (1989).
Posey et al., “A Pilot Trial of Vitzin, A Humanized Anti-Vitronection Receptor (anti αγβ3) Antibody in Patients with Metastatic Cancer”Cancer Biother. Radiopharm.16:125-132 (2001).
Rader et al., “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries,”Proc. Natl. Acad. Sci.95:8910-8915 (1998).
Reynolds et al., “Enhanced pathological angiogenesis in mice lacking β3integrin or β3and β5integrins,”Nature Medicine8:27-34 (2002).
Rosok et al., “A Combinatorial Library Strategy for the Rapid Humanization of Annticarcinoma BR96 Fab,”J. Biol. Chem.271:22611-22618 (1996).
Rudikoff et al. “Single amino acid substitution altering antigen-binding specificity,”Proc. Natl. Acad. Sci.79:1979-1983 (1982).
Sandberg and Terwilliger, “Engineering multiple properties of a protein by combinatorial mutagenesis,”Proc. Natl. Acad. Sci.90:8367-8371 (1993).
Schier et al., “Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections,”Hum. Antibod. Hybridomas, 7:97-105 (1996).
Schier et al., “Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection,”J. Mol. Biol., 255:28-43 (1996).
Schier et al., “Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions i
Huse William D.
Wu Herren
Applied Molecular Evolution, Inc.
Gambel Phillip
McDermott Will & Emery LLP
LandOfFree
αvβ3-specific antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with αvβ3-specific antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and αvβ3-specific antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4176763